Compare Stocks: ALPS, GLSI, BCYC, and GALT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPS ALPS Group Inc Ordinary Share	$0.40 -1.0%	$0.39	$0.23 ▼ $15.00	$65.89M	-0.1	59,054 shs	69,697 shs
BCYC Bicycle Therapeutics	$3.68 -1.3%	$4.02	$3.57 ▼ $9.16	$257.92M	1.54	423,838 shs	238,875 shs
GALT Galectin Therapeutics	$3.90 -1.5%	$3.72	$2.03 ▼ $7.13	$256.84M	0.38	329,378 shs	124,604 shs
GLSI Greenwich LifeSciences	$18.22 +0.7%	$15.84	$7.78 ▼ $34.10	$267.43M	1.47	127,136 shs	66,722 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPS ALPS Group Inc Ordinary Share	0.00%	-1.00%	-3.41%	-38.13%	+39,599,900.00%
BCYC Bicycle Therapeutics	0.00%	+0.82%	-15.01%	-10.24%	-51.45%
GALT Galectin Therapeutics	0.00%	+0.26%	-5.80%	-21.53%	-17.89%
GLSI Greenwich LifeSciences	0.00%	-4.05%	-2.72%	-7.93%	+66.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPS ALPS Group Inc Ordinary Share	$0.40 -1.0%	$0.39	$0.23 ▼ $15.00	$65.89M	-0.1	59,054 shs	69,697 shs
BCYC Bicycle Therapeutics	$3.68 -1.3%	$4.02	$3.57 ▼ $9.16	$257.92M	1.54	423,838 shs	238,875 shs
GALT Galectin Therapeutics	$3.90 -1.5%	$3.72	$2.03 ▼ $7.13	$256.84M	0.38	329,378 shs	124,604 shs
GLSI Greenwich LifeSciences	$18.22 +0.7%	$15.84	$7.78 ▼ $34.10	$267.43M	1.47	127,136 shs	66,722 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPS ALPS Group Inc Ordinary Share	0.00%	-1.00%	-3.41%	-38.13%	+39,599,900.00%
BCYC Bicycle Therapeutics	0.00%	+0.82%	-15.01%	-10.24%	-51.45%
GALT Galectin Therapeutics	0.00%	+0.26%	-5.80%	-21.53%	-17.89%
GLSI Greenwich LifeSciences	0.00%	-4.05%	-2.72%	-7.93%	+66.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPS ALPS Group Inc Ordinary Share	1.00	Sell	N/A	N/A
BCYC Bicycle Therapeutics	2.44	Hold	$13.86	276.55% Upside
GALT Galectin Therapeutics	2.00	Hold	$11.00	182.05% Upside
GLSI Greenwich LifeSciences	2.00	Hold	$69.00	278.70% Upside

Current Analyst Ratings Breakdown

Latest ALPS, GLSI, BCYC, and GALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	GLSI Greenwich LifeSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/14/2026	GALT Galectin Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/12/2026	GLSI Greenwich LifeSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/11/2026	GALT Galectin Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/30/2026	BCYC Bicycle Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$15.00 ➝ $14.00
7/21/2026	GLSI Greenwich LifeSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $69.00
7/13/2026	GALT Galectin Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/8/2026	BCYC Bicycle Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/6/2026	ALPS ALPS Group Inc Ordinary Share	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPS ALPS Group Inc Ordinary Share	$4.86M	13.56	N/A	N/A	($3.10) per share	-0.13
BCYC Bicycle Therapeutics	$61.21M	4.21	N/A	N/A	$8.79 per share	0.42
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.99) per share	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.03 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPS ALPS Group Inc Ordinary Share	-$2.01M	$0.33	1.20	N/A	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	-$218.96M	-$2.73	N/A	N/A	N/A	-311.11%	-33.22%	-27.79%	10/29/2026 (Estimated)
GALT Galectin Therapeutics	-$30.84M	-$0.43	N/A	N/A	N/A	N/A	N/A	-176.83%	11/13/2026 (Estimated)
GLSI Greenwich LifeSciences	-$19.36M	-$1.54	N/A	N/A	N/A	N/A	-793.81%	-295.32%	11/13/2026 (Estimated)

Latest ALPS, GLSI, BCYC, and GALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	GALT Galectin Therapeutics	-$0.09	-$0.14	-$0.05	-$0.14	N/A	N/A
8/11/2026	Q2 2026	GLSI Greenwich LifeSciences	-$0.33	-$0.27	+$0.06	-$0.27	N/A	N/A
7/30/2026	Q2 2026	BCYC Bicycle Therapeutics	-$0.5756	-$0.72	-$0.1444	-$0.72	$4.22 million	$0.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPS ALPS Group Inc Ordinary Share	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPS ALPS Group Inc Ordinary Share	N/A	0.36	0.27
BCYC Bicycle Therapeutics	N/A	12.08	12.08
GALT Galectin Therapeutics	N/A	0.10	0.10
GLSI Greenwich LifeSciences	N/A	1.54	1.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALPS ALPS Group Inc Ordinary Share	27.90%
BCYC Bicycle Therapeutics	86.15%
GALT Galectin Therapeutics	11.68%
GLSI Greenwich LifeSciences	4.16%

Insider Ownership

Company	Insider Ownership
ALPS ALPS Group Inc Ordinary Share	25.52%
BCYC Bicycle Therapeutics	22.00%
GALT Galectin Therapeutics	52.60%
GLSI Greenwich LifeSciences	51.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPS ALPS Group Inc Ordinary Share	89	166.40 million	123.94 million	N/A
BCYC Bicycle Therapeutics	288	69.99 million	54.60 million	Optionable
GALT Galectin Therapeutics	9	65.86 million	31.22 million	Optionable
GLSI Greenwich LifeSciences	13	14.68 million	7.12 million	Not Optionable

ALPS, GLSI, BCYC, and GALT Headlines

Recent News About These Companies

3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets

September 16, 2026 | finance.yahoo.com

BlackRock Inc. Purchases New Position in Greenwich LifeSciences, Inc. $GLSI

September 5, 2026 | marketbeat.com

Greenwich LifeSciences (NASDAQ:GLSI) Shares Down 0.7% - What's Next?

September 3, 2026 | marketbeat.com

Greenwich LifeSciences Extends Insider and Pre-IPO Share Lock-Up to January 31, 2027

August 10, 2026 | quiverquant.comQ

Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

August 10, 2026 | globenewswire.com

Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 1,500 Shares

July 30, 2026 | insidertrades.com

Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Buys 1,100 Shares of Stock

July 29, 2026 | insidertrades.com

Greenwich LifeSciences (NASDAQ: GLSI) - Share Price and Research

July 23, 2026 | intelligentinvestor.com.auI

Greenwich LifeSciences Announces UK Regulatory Approval to Expand Phase III FLAMINGO-01 Breast Cancer Trial

July 22, 2026 | quiverquant.comQ

Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom

July 22, 2026 | globenewswire.com

Greenwich LifeSciences Updates FLAMINGO-01 Phase III Trial Design, Enrollment and Financial Outlook

July 20, 2026 | quiverquant.comQ

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

July 20, 2026 | globenewswire.com

Greenwich LifeSciences Announces European Regulatory Review Allows Combined Enrollment of HLA-A*02 and Non-HLA-A*02 Patients in Phase III FLAMINGO-01 Trial

July 16, 2026 | quiverquant.comQ

Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

July 16, 2026 | globenewswire.com

Greenwich LifeSciences The Overlooked Need

July 16, 2026 | seekingalpha.com

Greenwich LifeSciences Shares Up After European Approval for Use of GP2 in Breast Cancer Immunotherapy Trial

July 10, 2026 | marketwatch.com

Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

July 9, 2026 | finanznachrichten.de

Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

July 9, 2026 | markets.businessinsider.com

Greenwich LifeSciences Announces EMA Approval for Commercially Manufactured GP2 in FLAMINGO-01 Across Europe

July 9, 2026 | quiverquant.comQ

Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

July 9, 2026 | globenewswire.com

GLSI stock climbs after removing a key overhang – retail turns focus to high-stakes breast cancer trial

June 2, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALPS, GLSI, BCYC, and GALT Company Descriptions

ALPS Group Inc Ordinary Share NASDAQ:ALPS

$0.39 -0.01 (-1.50%)

As of 09/25/2026 04:00 PM Eastern

ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.

Bicycle Therapeutics NASDAQ:BCYC

$3.68 -0.05 (-1.34%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$3.68 +0.00 (+0.14%)

As of 09/25/2026 07:30 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Galectin Therapeutics NASDAQ:GALT

$3.90 -0.06 (-1.52%)

As of 09/25/2026 04:00 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Greenwich LifeSciences NASDAQ:GLSI

$18.22 +0.12 (+0.66%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$17.99 -0.23 (-1.27%)

As of 09/25/2026 07:52 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALPS, GLSI, BCYC, and GALT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALPS, GLSI, BCYC, and GALT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALPS, GLSI, BCYC, and GALT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALPS, GLSI, BCYC, and GALT Company Descriptions

ALPS Group Inc Ordinary Share NASDAQ:ALPS

Bicycle Therapeutics NASDAQ:BCYC

Galectin Therapeutics NASDAQ:GALT

Greenwich LifeSciences NASDAQ:GLSI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALPS, GLSI, BCYC, and GALT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALPS, GLSI, BCYC, and GALT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALPS, GLSI, BCYC, and GALT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALPS, GLSI, BCYC, and GALT Company Descriptions

ALPS Group Inc Ordinary Share NASDAQ:ALPS

Bicycle Therapeutics NASDAQ:BCYC

Galectin Therapeutics NASDAQ:GALT

Greenwich LifeSciences NASDAQ:GLSI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools